Novo Nordisk is reducing the cash prices of its weight loss and diabetes drugs Wegovy and Ozempic by 30%, lowering the monthly cost to $349 from $499 for self-paying customers. The company also launched a limited-time offer allowing new patients to access the two lowest doses for $199 per month for the first two months, with the offer ending on March 31. These price cuts come amid increased competition from Eli Lilly, which has also reduced prices for its weight loss drug Zepbound, and efforts by the Trump administration to expand access and affordability of GLP-1 drugs through new deals and a government platform launching in early 2026. The deals aim to bring down the cost of these medications, which typically range from $1,000 to $1,350, to around $149 to $350 for consumers when purchased directly from manufacturers. Novo Nordisk's move is part of a broader strategy to expand access by building relationships with telehealth providers, major retailers, and government programs. The price reductions are expected to make Wegovy and Ozempic more affordable for Americans, especially those paying out-of-pocket, as public and private insurance coverage remains inconsistent, especially for weight loss indications.